Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218817 | 0.83 | ESR1 (0.46) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5214054 | 0.82 | KMT2A (0.51) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL6763972 | 0.78 | MET (0.39) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5215071 | 0.78 | ESR1 (0.47) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5379523 | 0.77 | ESR1 (0.45) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5218096 | 0.76 | KMT2A (0.41) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5214755 | 0.75 | ESR1 (0.45) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5217068 | 0.73 | ESR1 (0.47) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5220819 | 0.73 | GAA (0.44) | ESR1ESR2TDP1KMT2AMEN1 | |
| SCHEMBL5217499 | 0.72 | ESR1 (0.41) | ESR1ESR2TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885TDP1 3285/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885TDP1 3285/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885TDP1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.